BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China · Delayed Price · Currency is CNY

40.92

+0.65 (1.61%)

At close: Mar 6, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Income from sale of Products	1.15B	1.02B	877.52M	927.80M	670.46M
Income from sale of Products Growth	12.27%	16.63%	-5.42%	38.38%	73.52%
Income from Technology	39.22M	75.80M	84.39M	67.78M	47.01M
Income from Technology Growth	-48.26%	-10.17%	24.50%	44.17%	-40.60%
Equity Share Income	60.04M	61.90M	51.39M	54.58M	66.24M
Equity Share Income Growth	-3.02%	20.46%	-5.86%	-17.59%	76.42%
Total	1.25B	1.16B	1.01B	1.05B	783.71M
Total Growth	7.50%	14.59%	-3.51%	34.00%	55.78%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Export	575.46M	396.70M	441.36M	488.72M	407.79M
Export Growth	45.06%	-10.12%	-9.69%	19.85%	-
China	672.82M	764.48M	571.93M	561.43M	375.93M
China Growth	-11.99%	33.67%	1.87%	49.35%	-
Total	1.25B	1.16B	1.01B	1.05B	783.71M
Total Growth	7.50%	14.59%	-3.51%	34.00%	-

Source: S&P Global Market Intelligence.